导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.13% | 2387/4773 |
| 近一周 | -2.12% | 3423/5465 |
| 近一月 | -4.68% | 3404/5421 |
| 近一季 | -6.64% | 2488/5231 |
| 近半年 | -1.87% | 1920/4920 |
| 近一年 | 4.71% | 1807/4394 |
| 近两年 | 54.75% | 1375/2954 |
| 近三年 | 36.47% | 860/2253 |
| 成立以来 | 51.38% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.10% 3037/4961 |
14.35% 1838/5312 |
- - |
- - |
| 2025 | 24.75% 1772/4813 |
0.35% 1892/3635 |
1.30% 2390/4076 |
21.96% 1725/4524 |
0.62% 1893/4813 |
| 2024 | 18.45% 602/3463 |
3.30% 599/2808 |
-0.76% 832/3014 |
18.25% 1033/3129 |
-2.29% 2031/3463 |
| 2023 | -10.13% 1270/2656 |
4.84% 861/2280 |
-4.67% 1246/2385 |
-3.11% 850/2515 |
-7.20% 2084/2655 |
| 2022 | -20.62% 986/2207 |
-13.82% 849/1919 |
7.41% 482/2016 |
-15.29% 1264/2113 |
1.23% 1337/2208 |
| 2021 | -6.32% 1006/1822 |
-1.97% 564/1255 |
1.40% 1055/1330 |
-7.33% 1045/1466 |
1.70% 833/1822 |
| 2020 | 36.24% 398/1250 |
-10.86% 806/1028 |
13.07% 651/1067 |
16.19% 163/1164 |
16.34% 178/1184 |
| 2019 | - - |
- - |
- - |
2.11% 322/850 |
6.31% 630/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发中证A100ETF VS. 长安沪深300非周期A(740101) |